1-12 of 12
Mario Campone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities

Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, Stéphanie Durand, Angélique Abila, Delphine Centeno, Charlotte Joly, Bernard Lyan, Anne-Laure Martin, Sibille Everhard, Sandrine Boyault, Barbara Pistilli, Marion Fournier, Philippe Rouanet, Julie Havas, Baptiste Sauterey, Mario Campone, Carole Tarpin, Marie-Ange Mouret-Reynier, Olivier Rigal, Thierry Petit, Christine Lasset, Aurélie Bertaut, Paul Cottu, Fabrice André, Ines Vaz-Luis, Estelle Pujos-Guillot, Youenn Drouet, Olivier Trédan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4654–4666.
https://doi.org/10.1158/1078-0432.CCR-24-0195
Published: 15 October 2024
View article titled, Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities
Open the PDF for Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities in another window
Includes: Supplementary data
Journal Articles

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Matthew P. Goetz, Erika P. Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortes, Stephen Johnston, Antonio Llombart-Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2233–2244.
https://doi.org/10.1158/1078-0432.CCR-22-3573
Published: 15 May 2024
View article titled, Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Open the PDF for Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D. Kaulen, Jakob Ito, Martin van den Bent, Martin Taphoorn, Alba A. Brandes, Ahmed Idbaih, Julien Dômont, Paul M. Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3892–3900.
https://doi.org/10.1158/1078-0432.CCR-23-0926
Published: 02 October 2023
View article titled, Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Open the PDF for Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Özgüroğlu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 106–115.
https://doi.org/10.1158/1078-0432.CCR-20-3955
Published: 05 January 2022
View article titled, A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Open the PDF for A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

Aditya Bardia, Shanu Modi, Mafalda Oliveira, Javier Cortes, Mario Campone, Brigette Ma, Luc Dirix, Amy Weise, Becker Hewes, Ivan Diaz-Padilla, Yu Han, Priya Deshpande, Tanay S. Samant, Karen Rodriguez Lorenc, Wei He, Fei Su, Mariana Chavez-MacGregor
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6417–6428.
https://doi.org/10.1158/1078-0432.CCR-20-1068
Published: 15 December 2020
View article titled, Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Open the PDF for Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

Weimin Li, Joyce O'Shaughnessy, Daniel Hayes, Mario Campone, Igor Bondarenko, Irina Zbarskaya, Etienne Brain, Marina Stenina, Olga Ivanova, Marie-Pascale Graas, Patrick Neven, Deborah Ricci, Thomas Griffin, Thian Kheoh, Margaret Yu, Michael Gormley, Jason Martin, Michael Schaffer, Kathy Zelinsky, Peter De Porre, Stephen R.D. Johnston
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (24): 6002–6009.
https://doi.org/10.1158/1078-0432.CCR-15-2452
Published: 15 December 2016
View article titled, Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, Monika E. Hegi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4797–4806.
https://doi.org/10.1158/1078-0432.CCR-15-3153
Published: 02 October 2016
View article titled, Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <em>MGMT</em> Promoter Hypermethylation (EORTC 26082)
Open the PDF for Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <em>MGMT</em> Promoter Hypermethylation (EORTC 26082) in another window
Includes: Supplementary data
Journal Articles

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Jean-Yves Pierga, Thierry Petit, Christelle Lévy, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Jacques Bonneterre, Juana Hernandez, François-Clément Bidard, Patrice Viens
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1298–1304.
https://doi.org/10.1158/1078-0432.CCR-14-1705
Published: 12 March 2015
View article titled, Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2<sup>+</sup> Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
Open the PDF for Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2<sup>+</sup> Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data in another window
Journal Articles

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, Jose M. Perez-Garcia, Sara A. Hurvitz, Nicholas Turner, Hope Rugo, John W. Smith, Stephanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, Alejandro Yovine, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3693–3702.
https://doi.org/10.1158/1078-0432.CCR-13-0190
Published: 30 June 2013
View article titled, Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Open the PDF for Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Erica L. Mayer, Jean-Francois Baurain, Joseph Sparano, Lewis Strauss, Mario Campone, Pierre Fumoleau, Hope Rugo, Ahmad Awada, Oumar Sy, Antonio Llombart-Cussac
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6897–6904.
https://doi.org/10.1158/1078-0432.CCR-11-0070
Published: 31 October 2011
View article titled, A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer in another window
Journal Articles

A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients

Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, Christine Bobin-Dubigeon, Marie-Christine Etienne-Grimaldi, Michèle Boisdron-Celle, Françoise Serre-Debauvais, Frédéric Pinguet, Anne Floquet, Eliane Billaud, Chantal Le Guellec, Nicolas Penel, Mario Campone, Rémy Largillier, Olivier Capitain, Michel Fabbro, Nadine Houede, Jacques Medioni, Philippe Bougnoux, Isabelle Lochon, Etienne Chatelut
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3633–3639.
https://doi.org/10.1158/1078-0432.CCR-09-0017
Published: 18 May 2009
View article titled, A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients
Open the PDF for A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients in another window
Journal Articles

Vinflunine: A New Microtubule Inhibitor Agent

Jaafar Bennouna, Jean-Pierre Delord, Mario Campone, Laurent Nguyen
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1625–1632.
https://doi.org/10.1158/1078-0432.CCR-07-2219
Published: 17 March 2008
View article titled, Vinflunine: A New Microtubule Inhibitor Agent
Open the PDF for Vinflunine: A New Microtubule Inhibitor Agent in another window